News & Events

Armune BioScience Wins Best Poster of the AUA Moderated Poster Session at AUA 2017 in Boston, MA

Armune BioScience attended the 2017 American Urological Association (AUA) Annual Meeting in Boston on May 12–16. Armune’s poster, A Novel Serum Based Multiplexed 21 Autoantibody Assay to Predict High-grade Prostate Cancer at Initial Biopsy, received positive and meaningful feedback from attendees and ultimately won Best Poster of the Moderated Poster Session in the biomarkers category. […]

Armune BioScience Announces Agreement Retaining EMA Partners as Advisor and Investment Bank

KALAMAZOO, MICH. March 1, 2017 – Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available in the world to assess the risk for the presence of prostate cancer, announced today that the company has entered into a definitive agreement with EMA Partners (Denver, CO) retaining them as the company’s advisor […]

Premier Endpoint Interview with David Esposito of Armune BioScience

This is the first post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with David Esposito, President and Chief Executive Officer at Armune BioScience, Ann Arbor, Michigan (http://armune.com/). DAVID ESPOSITO: Armune BioScience is an early stage, medical diagnostics company started in […]

Armune BioScience, Inc. Announces the Closing of Series A Round of Financing

Funds will support the growth of commercial operations and research and development initiatives geared towards new tests in prostate, lung, and breast cancers. KALAMAZOO, MICH. September 07, 2016 — Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the closing of […]

Armune BioScience, Inc. Announces an Investment by the University of Michigan Investment Fund

$5 Million Series A investment round helps Armune, the developer of APIFINY, prepare for long term growth. KALAMAZOO, MICH. September 6, 2016 — Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the University of Michigan MINTS program has recently […]

Armune BioScience, Inc. Announces Tell Your Dad Campaign For National Prostate Cancer Awareness Month

KALAMAZOO, MICH. August 29, 2016 – Armune BioScience announced today the release of the Tell Your Dad campaign to coincide with Prostate Cancer Awareness Month. Anchored by a Presidential Proclamation, National Prostate Cancer Awareness Month is celebrated across the country with screenings, health fairs, media appearances, and other health education and outreach activities. The purpose […]

Armune BioScience, Inc. Receives State of Florida Clinical Laboratory License

Aeterna Zentaris Helps Coordinate Launch Plan in the Promotion of APIFINY, the Only Cancer Specific, Non-PSA Blood Test Available to Assess the Risk for the Presence of Prostate Cancer, to the Florida Market KALAMAZOO, MICH. August 8, 2016 – Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess […]

West Michigan is destination for life sciences startups

In its 2016 Annual Research Report, the Michigan Venture Capital Association revealed “Michigan-based venture capital firms have more capital under management than ever before: $2.2 billion, a 47 percent increase in capital used to power Michigan’s entrepreneurial economy in the last five years.” The report identified life sciences as one of the top two sectors […]